Journal of Immunology and Serum Biology

Citation: Scarisbrick, J.J., et al. Assessment of Peripheral Blood Tumour Burden in Mycosis Fungoides and Sézary Syndrome Shows Infrequent Involvement in Early and Tumour Stage Disease. (2015) J Immune Serum Biol 1(1): 17. 1Department of Dermatology, University Hospital Birmingham, Birmingham, UK 2Department of Haematology, University Hospital Birmingham, Birmingham, UK 3Wolfson Computer Laboratory, University Hospital Birmingham, Birmingham, UK 4Department of Oncology, University Hospital Birmingham, Birmingham, UK 5Department of Immunology, University Hospital Birmingham, Birmingham, UK 6West Midlands Regional Genetics Laboratory, Birmingham Women’s NHS Foundation Trust, UK

[1]  J. Scarisbrick,et al.  Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? , 2014, The British journal of dermatology.

[2]  L. Moscinski,et al.  Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis , 2013, Journal of Clinical Pathology.

[3]  C. Desmarais,et al.  Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma , 2013, Science Translational Medicine.

[4]  P. Hari,et al.  Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. , 2012, American journal of clinical pathology.

[5]  M. Borowitz,et al.  Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome. , 2011, American journal of clinical pathology.

[6]  R. Advani,et al.  Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). , 2011, Journal of the American Academy of Dermatology.

[7]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Bassett,et al.  Overall survival in erythrodermic cutaneous T‐cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T‐cell lymphoma , 2009, International journal of dermatology.

[9]  Nicola Pimpinelli,et al.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.

[10]  J. Katzmann,et al.  A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome. , 2006, American journal of clinical pathology.

[11]  J. Dongen,et al.  Validation of BIOMED-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies , 2004, Leukemia.

[12]  A. Varghese,et al.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.

[13]  P. Dubus,et al.  Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. , 2001, The Journal of investigative dermatology.

[14]  N. Dang,et al.  Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. , 2001, American journal of clinical pathology.

[15]  A. de Matteis,et al.  The relevance of the CD4+ CD26– subset in the identification of circulating Sézary cells , 2001, The British journal of dermatology.

[16]  H. Meyerson,et al.  Diminished CD3 expression is useful for detecting and enumerating Sézary cells. , 2000, American journal of clinical pathology.

[17]  T. Kuzel,et al.  Primary cutaneous B-cell lymphoma: review and current concepts. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Kurzrock,et al.  Prognostic factor analysis in mycosis fungoides/Sézary syndrome. , 1999, Journal of the American Academy of Dermatology.

[19]  M. Kashani-Sabet,et al.  Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. , 1999, Journal of the American Academy of Dermatology.

[20]  H. Kerl,et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.

[21]  A. Oseroff,et al.  Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. , 1997, Journal of the American Academy of Dermatology.

[22]  F. Foss,et al.  Immunophenotypic identification of Sezary cells in peripheral blood. , 1996, American journal of clinical pathology.

[23]  R. Martí,et al.  Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. , 1991, Archives of dermatology.

[24]  D. Byar,et al.  Clinical staging for cutaneous T-cell lymphoma. , 1984, Annals of internal medicine.

[25]  C. Meijer,et al.  Diagnostic criteria in Sézary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. , 1983, The Journal of investigative dermatology.

[26]  J. Bach,et al.  T cell imbalance in nonleukemic and leukemic cutaneous lymphoma defined by monoclonal antibodies. , 1981, Clinical immunology and immunopathology.

[27]  D. Byar,et al.  Prognostic variables in mycosis fungoides , 1981, Cancer.

[28]  B. Haynes,et al.  Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells. , 1981, The New England journal of medicine.

[29]  G. Goldstein,et al.  Cutaneous T cell lymphoma: characterization by monoclonal antibodies. , 1981, Blood.

[30]  P. Bunn,et al.  Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. , 1979, Cancer treatment reports.

[31]  P. Quaglino,et al.  Blood flow cytometry in Sézary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up. , 2015, American journal of clinical pathology.

[32]  Masaaki Ito,et al.  Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome. , 2010, Journal of dermatological science.

[33]  Ana Helena Santos,et al.  Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome. , 2003, Haematologica.

[34]  S. Whittaker,et al.  Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. , 2000, The Journal of investigative dermatology.